NCT07162259View on ClinicalTrials.gov

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Breast Neoplasms
Interventions
DRUG

First-line T-DXd followed by SG upon disease progression

Patients will be assigned to Cohort 1 (HER2 IHC 2+) based on different HER2 immunohistochemical expression levels, where they will first receive T-DXd treatment, followed by SG treatment upon disease progression.

DRUG

First-line SG followed by T-DXd upon progression

Patients will be assigned to Cohort 2 (HER2 IHC ≤1+) based on different HER2 immunohistochemical expression levels, where they will first receive SG treatment, followed by T-DXd treatment upon disease progression.

Trial Locations (1)

Unknown

Xi'an International Medical Center Hospital, Xi'an

All Listed Sponsors
lead

Yan Xue

OTHER